4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Enanta Pharmaceuticals, Inc. (ENTA) operates in the Biotechnology industry and is headquartered in Watertown, United States with about 120 employees. Its market capitalization is roughly $385 million. In the fiscal year ended 2025-09-30, ENTA reported $65M in revenue and ($82M) in net income.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
Interactive charts & full statements → Open the ENTA valuation workbench →
| Income statement | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Total Revenue | $65M | $68M | $79M | $86M | — |
| Operating Income (EBIT) | ($85M) | ($122M) | ($137M) | ($124M) | — |
| Net Income | ($82M) | ($116M) | ($134M) | ($122M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $17M | $19M | $15M | $18M | $15M |
| Operating Income (EBIT) | ($12M) | ($11M) | ($18M) | ($19M) | ($24M) |
| Net Income | ($13M) | ($12M) | ($19M) | ($18M) | ($23M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Total Assets | $281M | $377M | $462M | $375M | — |
| Total Liabilities | $216M | $248M | $246M | $54M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ENTA viewer.
About TickerBase · Data methodology & sources